ATE212998T1 - Kovalent vernetzte oligonukleotide - Google Patents

Kovalent vernetzte oligonukleotide

Info

Publication number
ATE212998T1
ATE212998T1 AT93907294T AT93907294T ATE212998T1 AT E212998 T1 ATE212998 T1 AT E212998T1 AT 93907294 T AT93907294 T AT 93907294T AT 93907294 T AT93907294 T AT 93907294T AT E212998 T1 ATE212998 T1 AT E212998T1
Authority
AT
Austria
Prior art keywords
strand
cross
covalently cross
linked oligonucleotides
linkages
Prior art date
Application number
AT93907294T
Other languages
English (en)
Inventor
Phillip Dan Cook
Muthian Manoharan
Thomas Bruice
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE212998T1 publication Critical patent/ATE212998T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93907294T 1992-03-05 1993-03-05 Kovalent vernetzte oligonukleotide ATE212998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84637692A 1992-03-05 1992-03-05
PCT/US1993/002059 WO1993018052A1 (en) 1992-03-05 1993-03-05 Covalently cross-linked oligonucleotides

Publications (1)

Publication Number Publication Date
ATE212998T1 true ATE212998T1 (de) 2002-02-15

Family

ID=25297748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907294T ATE212998T1 (de) 1992-03-05 1993-03-05 Kovalent vernetzte oligonukleotide

Country Status (8)

Country Link
US (1) US5719271A (de)
EP (1) EP0635023B1 (de)
JP (1) JP3530186B2 (de)
AT (1) ATE212998T1 (de)
CA (1) CA2131311C (de)
DE (1) DE69331543T2 (de)
IL (1) IL104965A (de)
WO (1) WO1993018052A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618704A (en) * 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5386023A (en) * 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5608046A (en) * 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5783682A (en) * 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
US5792844A (en) * 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5677437A (en) * 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5998603A (en) * 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5688941A (en) * 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US6087482A (en) * 1990-07-27 2000-07-11 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US6713602B1 (en) 1991-05-24 2004-03-30 Ole Buchardt Synthetic procedures for peptide nucleic acids
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
AT407639B (de) * 1993-12-13 2001-05-25 Christian Dr Noe Modifizierte oligonukleotide, verfahren zu ihrer herstellung und verwendung als wirkstoffe zur herstellung von arzneimitteln
FR2732344B1 (fr) * 1995-04-03 1997-06-20 Genset Sa Oligonucleotides a liaison covalente transversale, procede de preparation et synthon utile dans le procede
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) * 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6492111B1 (en) 1998-11-25 2002-12-10 Isis Pharmaceuticals, Inc. In situ binary synthesis of biologically effective molecules
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2002541825A (ja) * 1999-04-08 2002-12-10 オアシス バイオサイエンシーズ インコーポレイティッド ユニバーサル及び／又は同義性塩基を含むアンチセンスオリゴヌクレオチド
WO2000075303A1 (en) * 1999-06-07 2000-12-14 Kenshi Obaru Primers for polymerase reactions
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7105495B2 (en) * 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) * 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AU2003295387A1 (en) * 2002-11-05 2004-06-03 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
WO2005044976A2 (en) * 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
WO2005065321A2 (en) 2003-12-29 2005-07-21 Nugen Technologies, Inc. Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
JP5194256B2 (ja) * 2006-03-08 2013-05-08 国立大学法人東京工業大学 ２’水酸基修飾リボヌクレオシド誘導体
SG11201401628WA (en) 2011-10-19 2014-05-29 Nugen Technologies Inc Compositions and methods for directional nucleic acid amplification and sequencing
SG10201504490QA (en) 2012-01-26 2015-07-30 Nugen Technologies Inc Compositions And Methods For Targeted Nucleic Acid Sequence Enrichment And High Efficiency Library Generation
US9957549B2 (en) 2012-06-18 2018-05-01 Nugen Technologies, Inc. Compositions and methods for negative selection of non-desired nucleic acid sequences
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
US20140274738A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
WO2015073711A1 (en) 2013-11-13 2015-05-21 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
WO2015131107A1 (en) 2014-02-28 2015-09-03 Nugen Technologies, Inc. Reduced representation bisulfite sequencing with diversity adaptors
JP6803327B2 (ja) 2014-08-06 2020-12-23 ニューゲン テクノロジーズ， インコーポレイテッド 標的化されたシークエンシングからのデジタル測定値
JP6491233B2 (ja) * 2014-12-12 2019-03-27 国立研究開発法人産業技術総合研究所 ハイブリダイゼーション安定化用核酸複合体、核酸ハイブリダイゼーションの安定化方法、アンチセンス核酸医薬品及びｍｉｃｒｏＲＮＡ抑制剤
US12492430B2 (en) 2017-04-11 2025-12-09 Tecan Genomics, Inc. Library quantitation and qualification
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
US12059674B2 (en) 2020-02-03 2024-08-13 Tecan Genomics, Inc. Reagent storage system
EP4206325A4 (de) * 2020-08-25 2025-06-04 Tsumugi kosan K.K. Neuartiges nukleinsäuremolekül zur hemmung der expression eines zielgens
EP4229069A1 (de) 2020-10-13 2023-08-23 Universiteit Gent Verfahren zur proximitätsvermittelten kopplung eines ersten mittels an ein zweites mittel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123610A (en) * 1977-03-09 1978-10-31 The United States Government Nucleic acid crosslinking agent and affinity inactivation of nucleic acids therewith
US4868103A (en) * 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5082934A (en) * 1989-04-05 1992-01-21 Naxcor Coumarin derivatives for use as nucleotide crosslinking reagents
US4948494A (en) * 1989-06-28 1990-08-14 Union Oil Company Of California Removal of hydrogen sulfide from produced fluids
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
HUT62658A (en) * 1990-03-21 1993-05-28 Isis Pharmaceuticals Inc Reagent and process for modifying expression of gene by imitating rna
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5223618A (en) * 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
JPH06509945A (ja) * 1991-08-19 1994-11-10 マイクロプローブ・コーポレイション 酵素媒介三本鎖形成のための架橋性オリゴヌクレオチド
US5543507A (en) * 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides

Also Published As

Publication number Publication date
DE69331543D1 (de) 2002-03-21
JPH07504438A (ja) 1995-05-18
WO1993018052A1 (en) 1993-09-16
DE69331543T2 (de) 2002-09-26
EP0635023A4 (de) 1996-03-20
CA2131311A1 (en) 1993-08-16
CA2131311C (en) 2004-06-29
EP0635023A1 (de) 1995-01-25
IL104965A (en) 1999-11-30
EP0635023B1 (de) 2002-02-06
IL104965A0 (en) 1993-07-08
JP3530186B2 (ja) 2004-05-24
US5719271A (en) 1998-02-17

Similar Documents

Publication Publication Date Title
ATE212998T1 (de) Kovalent vernetzte oligonukleotide
EP0710667A3 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
AU1933195A (en) Modified oligonucleotide duplexes having anticancer activity
FI950254L (fi) Hybridi-oligonukleotidifosforotioaatteja
FR2731014B1 (fr) Molecules d'adn, preparation et utilisation en therapie genique
ZA964136B (en) Catalytic DNA.
EP0656790A4 (de) Zusammensetzungen und methoden zur modulation von rna.
DE3850812D1 (de) Mehrfachabzweigungs-Busleitungssystem.
DE69325404D1 (de) Leiterschicht-Anordnungen und das Herstellen ihrer elektrischen Verbindungen
BR8806222A (pt) Dispositivo de basculamento da aba de banco,e banco anatomico para veiculo automovel ou analogo
NO942257D0 (no) Polymerer, samt anvendelse av dem
FR2711989B1 (fr) Nouvelles isoquinoléines, leur préparation et leur utilisation comme médicaments.
OA09432A (fr) N-aryl-azétidinones, leur procédé de préparation et leur utilisation comme inhibiteurs des élastases.
EP1019436A4 (de) Erworbene resistenz npr gene und deren verwendungen
BR9401355A (pt) Oligonucleotídeo e nucleotídeo.
PT907358E (pt) Terapia de distribuicao uniforme de droga
EP0840743A4 (de) Auf die humanen mdr1- und mrp-gene gerichtete tharapeutische oligonukleotide
FI970740A7 (fi) Funktionaaliset terpyridiini-metallikompleksit, menetelmät niiden valmistamiseksi ja oligonukleotidikonjugaatit terpyridiini-metallikompleksien kanssa
NO873634D0 (no) Hybrid acryl-stjerne polymerer, og fremgangsmaate for fremstilling derav.
DE68909150D1 (de) Polymerisationsverfahren und Katalysatorsystem.
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
AU3422097A (en) Strand displacement amplification using boronated nucleotides
FR2693202B1 (fr) Polymères amphiphiles hydrosolubles, leur procédé de préparation et leur application comme épaississant.
DE69012330D1 (de) Katalysatorstripperanlage und -prozess bei katalytischen krackverfahren.
AU1774299A (en) Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment